Which Bisphosphonate? It's the Compliance!: Decision Analysis

Overview

Journal J Bone Metab

Date 2016 Jun 14

PMID 27294079

Citations 4

Authors

You Jin Lee

Chan Ho Park

Young-Kyun Lee

Yong-Chan Ha

Kyung-Hoi Koo

Affiliations

Soon will be listed here.

Abstract

Background: The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of life.

Methods: A decision analysis model was constructed containing final outcome score and the probability of vertebral and hip fracture within 1 year. Final outcome was defined as health-related quality of life, and was used as an utility in the decision tree. Probabilities were obtained by literature review, and health-related quality of life was evaluated by consensus committee. A roll back tool was used to determine the best bisphosphonate, and sensitivity analysis was performed to compensate for decision model uncertainty.

Results: The decision model favored bisphosphonate with higher compliance in terms of quality of life. In one-way sensitivity analysis, ibandronate was more beneficial than the others, when probability of compliance on ibandronate was above 0.589.

Conclusions: In terms of quality of life, the decision analysis model showed that compliance was most important for patients in real world, regardless of type of bisphosphonate.

Citing Articles

The Trend in the Sales of Menopausal Hormone and Other Osteoporosis Medications in South Korea from 2016 to 2019.

Lee E, Kwon S, Park H J Bone Metab. 2021; 28(3):201-206.

PMID: 34520653 PMC: 8441533. DOI: 10.11005/jbm.2021.28.3.201.

Medications for osteoporotic pain.

Shin S Korean J Pain. 2017; 30(2):85.

PMID: 28416990 PMC: 5392660. DOI: 10.3344/kjp.2017.30.2.85.

The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis.

Byun J, Jang S, Lee S, Park S, Yoon H, Yoon B J Bone Metab. 2017; 24(1):37-49.

PMID: 28326300 PMC: 5357611. DOI: 10.11005/jbm.2017.24.1.37.

Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment.

Jeong H, Cho S, Park S Endocrinol Metab (Seoul). 2016; 31(4):485-492.

PMID: 28029019 PMC: 5195822. DOI: 10.3803/EnM.2016.31.4.485.

References

Bernstein J . Decision analysis. J Bone Joint Surg Am. 1997; 79(9):1404-14. DOI: 10.2106/00004623-199709000-00018. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Cooper A, Drake J, Brankin E . Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006; 60(8):896-905. PMC: 1619408. DOI: 10.1111/j.1742-1241.2006.01059.x. View

Bilezikian J . Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009; 122(2 Suppl):S14-21. DOI: 10.1016/j.amjmed.2008.12.003. View

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

Weycker D, Macarios D, Edelsberg J, Oster G . Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2006; 18(3):271-7. DOI: 10.1007/s00198-006-0230-y. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Park C, Ha Y, Jang S, Jang S, Yoon H, Lee Y . The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29(6):744-51. DOI: 10.1007/s00774-011-0279-3. View

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T . GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2011; 23(1):223-31. DOI: 10.1007/s00198-011-1535-z. View

10.

Brauer C, Bozic K . Using observational data for decision analysis and economic analysis. J Bone Joint Surg Am. 2009; 91 Suppl 3:73-9. DOI: 10.2106/JBJS.H.01537. View

11.

Russell R, Watts N, Ebetino F, Rogers M . Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19(6):733-59. DOI: 10.1007/s00198-007-0540-8. View

12.

Landfeldt E, Strom O, Robbins S, Borgstrom F . Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2011; 23(2):433-43. DOI: 10.1007/s00198-011-1549-6. View

13.

Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E . Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007; 25(5):302-9. DOI: 10.1007/s00774-007-0768-6. View

14.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

15.

Lee Y, Nho J, Ha Y, Koo K . Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2011; 23(9):2329-33. DOI: 10.1007/s00198-011-1881-x. View

16.

Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-41. DOI: 10.1016/s0140-6736(96)07088-2. View

17.

Siris E, Selby P, Saag K, Borgstrom F, Herings R, Silverman S . Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009; 122(2 Suppl):S3-13. DOI: 10.1016/j.amjmed.2008.12.002. View

18.

Cramer J, Gold D, Silverman S, Lewiecki E . A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007; 18(8):1023-31. DOI: 10.1007/s00198-006-0322-8. View

19.

Kertes J, Dushenat M, Vesterman J, Lemberger J, Bregman J, Friedman N . Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J. 2008; 10(3):207-13. View